KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $15.7 billion.

  • Bristol Myers Squibb's Cash & Equivalents rose 9931.56% to $15.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 billion, marking a year-over-year increase of 9931.56%. This contributed to the annual value of $10.3 billion for FY2024, which is 975.23% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported Cash & Equivalents of $15.7 billion as of Q3 2025, which was up 9931.56% from $12.6 billion recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year Cash & Equivalents high stood at $15.7 billion for Q3 2025, and its period low was $6.3 billion during Q2 2024.
  • For the 5-year period, Bristol Myers Squibb's Cash & Equivalents averaged around $10.5 billion, with its median value being $10.8 billion (2022).
  • As far as peak fluctuations go, Bristol Myers Squibb's Cash & Equivalents tumbled by 4469.75% in 2021, and later skyrocketed by 10020.66% in 2025.
  • Bristol Myers Squibb's Cash & Equivalents (Quarter) stood at $14.0 billion in 2021, then crashed by 34.74% to $9.1 billion in 2022, then grew by 25.66% to $11.5 billion in 2023, then decreased by 9.75% to $10.3 billion in 2024, then skyrocketed by 52.0% to $15.7 billion in 2025.
  • Its Cash & Equivalents stands at $15.7 billion for Q3 2025, versus $12.6 billion for Q2 2025 and $10.9 billion for Q1 2025.